Acorda Therapeutics (ACORQ) S-3/A Shelf registration (amended)

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 12.1

STATEMENT REGARDING COMPUTATION OF RATIOS

				Year Ended December 31,												Year Ended June 30,
	Nine Months Ended September 30, 2007												Six Months Ended December 31, 2003
				2006			2005			2004						2003			2002
	(in thousands)
Determination of earnings:
Income (loss) from operations	$	(24,245	)	$	(60,027	)	$	(60,380	)	$	(69,487	)	$	(48,697	)	$	(50,054	)	$	(21,236	)
Add:
Fixed charges		2,459			2,849			1,760			606			332			662			562
Earnings, as adjusted	$	(21,786	)	$	(57,178	)	$	(58,620	)	$	(68,881	)	$	(48,365	)	$	(49,392	)	$	(20,674	)
Fixed charges:
Interest expense	$	2,209		$	2,553		$	1,526		$	385		$	222		$	447		$	408
Amortization of capitalized expenses related to indebtedness		57			73			12			—			—			—			—
Portion of rent representative of the interest factor(1)		193			223			222			221			110			215			154
Fixed charges	$	2,459		$	2,849		$	1,760		$	606		$	332		$	662		$	562
Preferred stock dividends (no dividends paid)		—			604			5,341			5,188			2,211			630			—
Ratio of earnings to fixed charged		*			*			*			*			*			*			*
Deficiency of earnings available to cover fixed charges	$	(24,245	)	$	(60,631	)	$	(65,721	)	$	(74,675	)	$	(50,908	)	$	(50,684	)	$	(21,236	)

*

Less than one to one coverage

(1)

Approximately 33% of annual rent expense is included in the computation. The Company believes this is a reasonable estimate of the interest factor in its leases, which is not material. The underlying rent amounts were $583,000, $677,000, $673,000, $670,000, $334,000, $652,000, and $468,000 for the nine months ended September 30, 2007, the years ended December 31, 2006, 2005 and 2004, the six months ended December 31, 2003, and the years ended June 30, 2003 and 2002, respectively.

QuickLinks

Exhibit 12.1

STATEMENT REGARDING COMPUTATION OF RATIOS